1. Medicine

Category Archives: Medicine

Institute for Regenerative Medicine to Lead National Effort to Aid Wounded Warriors

Posted on by

Newswise WINSTON-SALEM, N.C. Sept. 27, 2013 The Institute for Regenerative Medicine at Wake Forest University School of Medicine (Wake Forest Baptist Medical Center) has been selected to lead the second phase of the Armed Forces Institute of Regenerative Medicine (AFIRM). The five-year, $75 million federally funded project focuses on applying regenerative medicine to battlefield injuries.

Anthony Atala, M.D., director of the Wake Forest Institute for Regenerative Medicine, is the lead investigator for AFIRM-II. He will direct a consortium of more than 30 academic institutions and industry partners. Assisting him is co-director Rocky S. Tuan, Ph.D., associate director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh.

The first phase of AFIRM, which began in 2008, resulted in clinical studies of face transplantation, minimally invasive surgery for craniofacial injuries, a lower-dose anti-rejection regimen after kidney transplantation, scar reduction treatments, fat grafting for reconstructive surgery and new treatments for burns. Atala was co-leader of AFIRM-I, which was comprised of two research consortiums.

The AFIRM-I teams were charged with conducting at least one clinical study of a new treatment for wounded warriors, said Atala. Instead, due to their expertise, collaborative spirit and dedication to the mission, there were more than 10 clinical studies of potential new therapies. We are honored to have the opportunity to continue this important work to benefit those who serve our country.

Regenerative medicine is a science that takes advantage of the bodys natural healing powers to restore or replace damaged tissue and organs. Therapies developed by AFIRM can also benefit people in the civilian population. AFIRM is a results-focused program that not only funds scientific research, but requires that discoveries be tested and compared so that the most promising therapies can be brought to clinical trials.

When warriors come back from the battlefield with serious life-changing injuries, it is our job to find new and innovative ways to help them. Ultimately, wed like to create new treatments to repair these severe injuries as if they never happened, said Maj. Gen. Joseph Caravalho Jr., commanding general of the U.S. Army Medical Research and Materiel Command and Fort Detrick. The science of regenerative medicine is one of the ways we fulfill our promise to service members who put themselves in harms way, that we will work our hardest and do our very best to take care of them.

The AFIRM-II team will focus on developing clinical therapies over the next five years focusing on: Restoring function to severely traumatized limbs Reconstruction for facial and skull injuries through tissue regeneration Skin regeneration for burn injuries New treatments to prevent rejection of composite transplants such as face and hands Reconstruction of the genital and urinary organs and lower abdomen including the bladder, anal sphincter and external genitalia

Members of the AFIRM-II team, known as the Warrior Restoration Consortium, are Brigham and Women's Hospital, Case Western Reserve University, Cleveland Clinic, Georgia Institute of Technology, Jewish Hospital, Johns Hopkins University, Livionex Inc., Massachusetts General Hospital, Mayo Clinic, New York University School of Medicine, Northwestern University, Oregon Health & Science University, Radboud University Medical Center, Research Foundation of SUNY, Rice University, Stanford University School of Medicine, Rutgers -The State University of New Jersey, Southwest Research Institute, Stratatech Corporation, The Ohio State University College of Medicine, Tufts University, University of California, Los Angeles, University of Cincinnati, University of Connecticut, University of Florida, University of Louisville School of Medicine, University of Maryland School of Medicine, University of Michigan, University of Pittsburgh, UW Medicine, Vanderbilt University Medical Center, Wake Forest University School of Medicine (Wake Forest Baptist Medical Center).

The academic-industry team will work with health professionals at the U.S. Army Institute of Surgical Research and Walter Reed National Military Medical Center to develop new treatments for wounded soldiers. Government sponsors of AFIRM are the U.S. Army Medical Research and Materiel Command, the Office of Naval Research, the Air Force Medical Service, the Office of Research and Development - Department of Veterans Affairs, the National Institutes of Health, and the Office of the Assistant Secretary of Defense for Health Affairs.

# # #

Read more:

Institute for Regenerative Medicine to Lead National Effort to Aid Wounded Warriors

Combining Chinese and Western medicine could lead to new cancer treatments

Posted on by

Public release date: 27-Sep-2013 [ | E-mail | Share ]

Contact: Chris Jones jonesc83@cardiff.ac.uk 029-208-74731 Cardiff University

Combining traditional forms of Chinese and Western medicine could offer new hope for developing new treatments for liver, lung, colorectal cancers and osteosarcoma of the bones.

Experts from Cardiff University's School of Medicine have joined forces with Peking University in China to test the health benefits of a traditional Chinese medicine.

The team also set-out to examine how by combining it with more traditional methods like Chemotherapy could improve patient outcomes and potentially lead to the development of new cancer treatments and therapies.

"Traditional Chinese medicine where compounds are extracted from natural products or herbs has been practised for centuries in China, Korea, Japan and other countries in Asia," according to Professor Wen Jiang from Cardiff University's School of Medicine, who is the director of the Cardiff University-Peking University Joint Cancer Institute at Cardiff and led the research as part of a collaboration between Cardiff University and Peking University.

"Although a few successes, most of the traditional remedies are short of scientific explanation which has inevitably led to scepticism especially amongst traditionalists in the West.

"As a result, we set out to test the success of a Chinese medicine and then consider how combining it alongside traditional methods like Chemotherapy could result in positive outcome for patients," he adds.

Yangzheng Xiaoji is a traditional Chinese formula consisting of 14 herbs. The formula has been shown to be beneficial to cancer patients however, until now how it works has remained unknown.

Since 2012 the Team have investigated how the formula works, discovering that it works by blocking a pathway which stops the spread of cancer cells in the body.

More here:

Combining Chinese and Western medicine could lead to new cancer treatments

Modernizing Medicine(R) Receives 2013 Florida Fast 100 Award

Posted on by

BOCA RATON, FL--(Marketwired - Sep 27, 2013) - Modernizing Medicine, Inc., has been recognized by the Florida Business Journals as one of the 100 Fastest Growing Companies in the State of Florida. The company ranked third out of the entire group of stellar companies.

"We work hard to meet the demand for healthcare technology that truly helps doctors be more efficient," said Daniel Cane, President and CEO of Modernizing Medicine. "Our company has grown into new specialties this year and we look forward to helping a wider range of physicians in the year ahead. We thank the Florida Business Journals for acknowledging our hard work and momentum."

Each year the Business Journals ranks Florida's fastest-growing private companies to come up with the prestigious 'Fast 100.' Companies chosen show a range of industries, including real estate development, manufacturing, technology, healthcare and retail, and in size and annual revenue. The companies are ranked by one-year percentage growth. Last year, Modernizing Medicine ranked #1 among the winners of the 'Fast 50' companies in South Florida, an award given by the South Florida Business Journal.

Details about the 'Fast 100' and the full list of honorees are available on the Business Journals' website. The official company rankings were announced during the awards ceremony on September 27th in Orlando, Florida.

About Modernizing Medicine

Modernizing Medicine is transforming how healthcare information is created, consumed and utilized in order to increase efficiency and improve outcomes. Our product, Electronic Medical Assistant (EMA), is a cloud-based, specialty-specific electronic medical record (EMR) system with a massive library of built-in medical content, designed to save physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each provider's unique style of practice and is designed to interface with hundreds of different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, optometry, orthopedics, otolaryngology and plastic and cosmetic surgery markets, and to more than 1,000 physician practices across the country. In 2013 Modernizing Medicine was listed on Forbes' annual ranking of America's Most Promising Companies.

Continued here:

Modernizing Medicine(R) Receives 2013 Florida Fast 100 Award

Steve Jobs Left a Legacy on Personalized Medicine

Posted on by

A type of DNA test the Apple CEO hoped might save his life is becoming widely available.

Final slide: In 2011, Steve Jobs spent $100,000 to discover the genetic basis of the cancer that killed him.

If you need proof of how information technology is influencing biotech, take a look at Foundation Medicine, the Boston-area diagnostics company that went public on Wednesday.

Its stock price quickly doubled after the IPO. And one reason is surely its links to stratospheric tech names from the West Coast. The company is backed by both Google and Bill Gates, and the core idea behind its technology was once tried out on Apple founder Steve Jobs.

Foundation sells a $5,800 test that looks in detail at the DNA of a person with cancer. The concept is that a comprehensive catalogue of genetic mutations in a persons tumor will show exactly whats driving the cancer and help doctors choose what drug will work best (see Foundation Medicine: Personalizing Cancer Drugs.)

It turns out that Jobs was one of the first peopleand certainly the best-knownto try this kind of all-in genetic strategy to beat cancer. As recounted in Walter Isaacsons biography of the Apple CEO, Jobs spent $100,000 to learn the DNA sequence of his genome and that of the tumors killing him. Jobs was jumping between treatments and hoped DNA would provide clues about where to turn next.

One of Jobss doctors I spoke to indicated that in the end DNA did not prove key to steering his treatment. But Jobs believed that medicine was taking strides. He famously said, Im either going to be one of the first to be able to outrun a cancer like this, or Im going to be one of the last to die from it.

According to Isaacson, some of the DNA analysis was done by the Broad Institute of MIT and Harvard, and his book tells how researchers travelled to California to brief Jobs five months before his death in 2011. While Broad wasnt able to confirm its role to me (events around Jobss illness are still closely guarded), by the time Jobs died four of the institutes top scientists were already deeply involved in setting up Foundation Medicine, which is based on their work studying cancer mutations.

The companys test, called FoundationOne, essentially offers the public the same type of DNA screening information that Jobs was among the first to get. Its a test that sequences 236 genes involved in cancer, detailing the dangerous mutations that are causing them to grow.

Google and Gates are two of the largest investors in Foundation Medicinethey own 9 percent and 4 percent of the company, respectively. One motive for their investment, I think, is that DNA is a profoundly digital molecule. And now that its become very cheap to decode, genetic data is piling up by the terabyte. Tech executives understand that and can see how to make a business out of it.

Follow this link:

Steve Jobs Left a Legacy on Personalized Medicine

Galax-C – ”Medicine Cabinet” (Prod. Chris Calor) *NEW* *SEPTEMBER* 720p – Video

Posted on by


Galax-C - #39; #39;Medicine Cabinet #39; #39; (Prod. Chris Calor) *NEW* *SEPTEMBER* 720p
What was going to be the Intro for the highly anticipated mixtape One 800 comes out sometime in October for futher notice make sure to follow us on Twitter,I...

By: Guich Boyz

Go here to read the rest:

Galax-C - ''Medicine Cabinet'' (Prod. Chris Calor) *NEW* *SEPTEMBER* 720p - Video

Daniel Bryan WINS – The Shield Gets a Taste of Their Own Medicine – YES! – Reaction by JDV – Video

Posted on by


Daniel Bryan WINS - The Shield Gets a Taste of Their Own Medicine - YES! - Reaction by JDV
YES! Daniel Bryan wins, pinning Seth Rollins and defeating The Shield in a huge tag match with the many WWE Superstars supporting Daniel Bryan in a tag match...

By: Conservative New Media

See original here:

Daniel Bryan WINS - The Shield Gets a Taste of Their Own Medicine - YES! - Reaction by JDV - Video

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation …

Posted on by

NEW YORK, Sept. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017 http://www.reportlinker.com/p01650887/Nuclear-Medicine-Market--Radiopharmaceuticals-%5BSPECT/PET-Radioisotopes-Technetium-F-18%5D-%5BBeta/Alpha-radiation-therapy-I131-Y-90%5D-%5BApplications-Cancer/Oncology-Cardiac%5D--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017

The global radiopharmaceuticals market was valued at $3.8 billion in 2012 and is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, North America, Japan, the Republic of Korea, and Oceania between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

North America is the dominant market for diagnostic radioisotopes with 49% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) - in 2012; they jointly contributed more than 90% to the global revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

View original post here:

Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation ...

Penn Medicine's Garret FitzGerald Named Ohio State Heart Program 2013 Schottenstein Laureate

Posted on by

Newswise PHILADELPHIA - Garret FitzGerald, MD, FRS, professor of Medicine and Pharmacology; chair of the Department of Pharmacology; and director of the Institute for Translational Medicine and Therapeutics at the Perelman School of Medicine, University of Pennsylvania is the 2013 recipient of the Jay and Jeanine Schottenstein Prize in Cardiovascular Sciences from The Ohio State University Wexner Medical Centers Heart and Vascular Center.

The Schottenstein Prize, established with a $2 million gift from philanthropists Jay and Jeanie Schottenstein, is awarded to an international leader in the clinical sciences of cardiovascular medicine, cardiothoracic surgery, or the basic sciences of molecular or cellular cardiology. With the gift, the Schottenstein Laureate receives an honorarium of at least $100,000. FitzGerald will receive the award, one of the largest in the field, during a ceremony in Columbus on Oct 2.

I am honored to receive this prize, which reflects on the dedication and hard work of so many people with whom Ive been privileged to work and collaborate, says FitzGerald.

His research takes an integrative approach to elucidating the mechanisms of drug action, drawing on work in cells, model organisms, and humans. His work contributed substantially to the development of low-dose aspirin for cardioprotection. His team discovered how lower doses of aspirin than had been previously used to treat pain and inflammation act on blood cells called platelets to shut down their role in blocking arteries to cause heart attacks and strokes. Low-dose aspirin is now used for this purpose throughout the world and has saved the lives of tens of millions of people. His group was also the first to predict and then mechanistically explain the cardiovascular hazard from nonsteroidal antinflammatory drugs - NSAIDs. Between his work on aspirin and NSAIDs, he has benefited ten, if not hundreds, of millions of patients worldwide. His laboratory also described the first molecular clock in the cardiovascular system.

While in Columbus, FitzGerald will lecture during a special Grand Rounds in the Richard M. Ross Heart Hospital and meet with cardiovascular researchers at the Dorothy M. Davis Heart and Lung Research Institute.

For more information view the Ohio State release.

### Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.

Go here to read the rest:

Penn Medicine's Garret FitzGerald Named Ohio State Heart Program 2013 Schottenstein Laureate

Penn Medicine Radiation Oncology Chair Named Among 2013 ASTRO Fellows

Posted on by

ATLANTA Stephen M. Hahn, MD, chairman of the Department of Radiation Oncology and Henry K. Pancost Professor of Radiation Oncology in the Perelman School of Medicine and Abramson Cancer Center at the University of Pennsylvania, has been named among the ten 2013 Fellows of the American Society for Radiation Oncology.

Dr. Hahn became the chair of Penn Medicines Department of Radiation Oncology in 2005, after joining Penns faculty in 1996. During his tenure, he has overseen the opening of the Roberts Proton Therapy Center, the worlds largest and most advanced center integrating both proton beam radiation therapy and conventional radiation.

He received the FASTRO recognition this week during the organizations 55th Annual Meeting at the Georgia World Congress Center in Atlanta.

Awarded annually since 2006, ASTROs Fellows Program honors radiation oncology leaders who have been an ASTRO member for at least 15 years and have made substantial contributions to the field of radiation oncology in the areas of research, education, patient care or service, and leadership. Including the 2013 class of 10 Fellows, 212 of ASTROs more than 10,000 members worldwide have received the FASTRO designation.

Prior to his arrival at Penn, Dr. Hahn served as chief of the National Cancer Institutes Prostate Cancer Clinic, Clinical Pharmacology Branch, in Bethesda, MD, and as senior investigator at the NCI. He also served as a Commander in the NCIs U.S. Public Health Service from 1989 to 1995.

Dr. Hahns research and clinical care concentrates on cancers of the lung and genitourinary system, as well as radiation biology and photodynamic therapy. He is board certified in Internal Medicine, Radiation Oncology, and Hematology/Oncology, and is a graduate of the Temple University School of Medicine and Rice University. He completed his internal medicine residency atthe University of California, San Francisco and received fellowship training in both medical oncology and radiation oncology at the NCI. He has been a longtime member and leader of various ASTRO committees and initiatives.

These 10 new Fellows join an elite group of ASTRO members who have significantly impacted ASTRO, the specialty and cancer patients worldwide through their leadership in and service to research, education and patient care efforts, said ASTRO President Colleen A. F. Lawton, MD, FASTRO. Congratulations to my esteemed colleagues on receiving the ASTRO Fellow designation.

To read more about the 2013 FASTRO awardees, visit the ASTRO web site.

View post:

Penn Medicine Radiation Oncology Chair Named Among 2013 ASTRO Fellows


  1. Medicine